These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30979702)

  • 1. PD-1 Blockade in GBM: Uncovering Response Clues.
    Cancer Discov; 2019 Jun; 9(6):687-688. PubMed ID: 30979702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.
    Restrepo P; Yong R; Laface I; Tsankova N; Nael K; Akturk G; Sebra R; Gnjatic S; Hormigo A; Losic B
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31907277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
    Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
    Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
    Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
    Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
    Chau I
    Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapies for the Treatment of Glioblastoma in Adults.
    Chuang DF; Lin X
    Curr Oncol Rep; 2019 May; 21(7):61. PubMed ID: 31102038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.
    De Felice F; Musio D; Cassese R; Gravina GL; Tombolini V
    Curr Cancer Drug Targets; 2017; 17(3):282-289. PubMed ID: 27528363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma Therapy in the Age of Molecular Medicine.
    Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
    Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
    Zhao J; Chen AX; Gartrell RD; Silverman AM; Aparicio L; Chu T; Bordbar D; Shan D; Samanamud J; Mahajan A; Filip I; Orenbuch R; Goetz M; Yamaguchi JT; Cloney M; Horbinski C; Lukas RV; Raizer J; Rae AI; Yuan J; Canoll P; Bruce JN; Saenger YM; Sims P; Iwamoto FM; Sonabend AM; Rabadan R
    Nat Med; 2019 Mar; 25(3):462-469. PubMed ID: 30742119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Roth P; Valavanis A; Weller M
    Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
    [No Abstract]   [Full Text] [Related]  

  • 16. BTK/PD-1 blockade for treatment of Richter's transformation.
    Tang PS; Tam CS
    Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
    [No Abstract]   [Full Text] [Related]  

  • 17. Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report.
    Kartal Ö; Ataş E
    Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30404191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
    Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
    J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The path forward for anti-programmed cell death-1 therapy in gliomas.
    Majd N; Kamiya-Matsuoka C; de Groot J
    Curr Opin Neurol; 2019 Dec; 32(6):864-871. PubMed ID: 31567548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Immunotherapeutic Approaches for Glioblastoma.
    Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
    J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.